IMRX
Immuneering Shares up 50% After Positive Mid-Stage Trial Data for Pancreatic Cancer Therapy
时间：2025-01-07 22:31:09 市场： 美股 综合
Immuneering Shares up 51.7% Premarket After Positive Mid-Stage Trial Data for Pancreatic Cancer Therapy
时间：2025-01-07 20:27:33 市场： 美股 综合
Immuneering Granted FDA Fast Track Designation for Imm-1-104 in Advanced Melanoma
时间：2024-12-12 21:00:01 市场： 美股
Immuneering Shares up 35.7% at $1.94 Premarket After Cancer Therapy Shows Promising Results in Trial
时间：2024-09-13 16:04:43 市场： 美股 综合
Immuneering Shares Surge After 'Positive' Data in Phase 2a Pancreatic Cancer Trial Immuneering (IMRX) shares surged 52% in after-hours activity Thursday after the company said complete or partial response was observed in the first two patients with first-line pancreatic cancer getting IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel in a phase 2a study.The initial response rate in the trial was 40% while the initial disease control rate was 80%, the company said Thursday in a statement.All five patients in the study are continuing treatment after "positive initial response data," Immuneering said.Additional patients were dosed with 320 milligrams once daily, and the drug is well tolerated in combination with gemcitabine/nab-paclitaxel, the company said.Price: 2.17, Change: +0.74, Percent Change: +51.75
时间：2024-09-13 05:11:31 市场： 美股 综合
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses With Imm-1-104 in Combination With Chemotherapy in First-Line Pancreatic Cancer Patients
时间：2024-09-13 04:05:01 市场： 综合 美股